CARDIO H - N°68 / DÉCEMBRE 2024
notherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial Kim, Byeong-Keuk et al. The Lancet, Volume 400, Issue 10349, 380 – 390 8. Article Cardio Online sur les effets secondaires musculaires des statines par Dr Antonio Gallo (Service d’endocrinologie-métabo- lisme, Hôpital Pitié-Salpêtrière (APHP) et Institut Hospitalo-Uni- versitaire cardiométabolique, Paris), 2021, consulté [14/11/2024] sur https://www.cardio-online.fr/Actualites/A-la-une/Les-ef- fets-secondaires-musculaires-des-statines 9. Article Vidal Chronothérapie et système cardiovasculaire : te- nir compte de «l’autre» rythme du coeur ? par Patricia Thelliez , 2019, consulté 14/11/2024] sur https://www.vidal.fr/actua- lites/24044-chronotherapie-et-systeme-cardiovasculaire-tenir-co mpte-de-l-autre-rythme-du-coeur.html#: ~ :text=Le%20taux%20 d’HMG%20CoA,enzyme%20que%20ciblent%20les%20statines 10. Ray KK et al. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinatio- nal observational SANTORINI study. Atheroscler Plus. 2021 Aug 13;43:24-30. doi: 10.1016/j.athplu.2021.08.003. PMID: 36644508; PMCID: PMC9833224.
2. ESC Scientific Document Group , 2021 ESC Guidelines on car- diovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the Eu- ropean Association of Preventive Cardiology (EAPC), European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3227– 3337, https://doi.org/10.1093/eurheartj/ehab484 3. Collins R et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532- 2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Erratum in: Lancet. 2017 Feb 11;389(10069):602. doi: 10.1016/ S0140-6736(16)31468-4. PMID: 27616593. 4. Ballantyne CM, et al GRAVITY Study Investigators. Efficacy, safety and effect on biomarkers related to cholesterol and lipo- protein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk pa- tients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan;232(1):86-93. doi: 10.1016/j.atherosclerosis.2013.10.022. Epub 2013 Nov 1. PMID: 24401221. 5. Résumé des caractéristiques du produit (RCP) Rosuvastatine 6. Résumé des caractéristiques du produit (RCP) Simvastatine 7. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin mo-
Avec le soutien institutionnel
COLLÈGE NATIONAL DES CARDIOLOGUES DES HÔPITAUX
19 - 20 - 21 novembre
2025 Paris
DU 19 AU 21 NOVEMBRE 2025 PARIS
25
Made with FlippingBook. PDF to flipbook with ease